" class="no-js "lang="en-US"> PRISM BioLab Enters Multi-Project Drug Discovery Collaboration with Roche and Genentech - Medtech Alert
Tuesday, March 21, 2023

Breaking News

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis Gamida Cell Announces Changes to Board of Directors Newron Reports Topline Results From All Patients in Study Evaluating Evenamide as Add-on Therapy for Treatment-Resistant Schizophrenia Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer TFS HealthScience Expands Operations into Israel, With Focus on Continuous, Rapid International Expansion
PRISM BioLab

January 5 2022

PRISM BioLab Enters Multi-Project Drug Discovery Collaboration with Roche and Genentech

PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group.

Under the terms of the agreement, PRISM BioLab will provide its proprietary library of peptide mimetic small molecules, the PepMetics Library, for screening against targets selected by Roche and Genentech. Upon identification of hit compounds, Roche and Genentech may elect to further develop and commercialize the compounds.

PRISM BioLab is eligible to receive an upfront payment, success-based milestone payments and royalties on future net sales. Specific financial terms are not disclosed.

Companies In This Post

Roche | Pharmtech Focus

Roche
Genentech | Pharmtech Focus

Genentech
PRISM BioLab | Pharmtech Focus

PRISM BioLab
  1. Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors

    Appointments

     Read more
  2. Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

    Clinical Trials

     Read more
  3. BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey

    News

     Read more
  4. Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution

    Fundraising

     Read more
  5. GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

    Diseases

     Read more
More On